Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
December 8, 2003
- Alfresa Holdings: Fukujin, Azwell Show Mixed Results
December 8, 2003
- BULLETIN
December 8, 2003
- Astis: Consolidated Sales Down 2.1% at \43,756 Mil.
December 8, 2003
- Basic Policy on National Hospital Organization Issued
December 8, 2003
- Seiwa Sangyo: Consolidated Sales Rise 4.8% to \43.6 Bil.
December 8, 2003
- Nurse to Participate in Chuikyo as Expert Member
December 8, 2003
- Tsumura: Sales of Ethical Kampo Down 3.4%
December 8, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 8, 2003
- Zeria: Consumer Healthcare Brisk, but Ethical Sluggish
December 8, 2003
- Press Seminar
December 8, 2003
- SSP: Sales of OTC Products Down 4.8% to \23.8 Bil.
December 8, 2003
- Semi-annual Business Result
December 8, 2003
- Mutual GMP Recognition Discussed: MOSS Followup Talks
December 1, 2003
- PRESS SEMINAR
December 1, 2003
- Semi-annual Business Results
December 1, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 1, 2003
- Mochida: Profits Decline Despite Slight Growth in Pharma Sales
December 1, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 1, 2003
- Fuso: Profits Marked for 1st Time in 3 Years
December 1, 2003
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…